The pump currently in development allows users to change sites without a phone—potentially reshaping the tubeless landscape and pushing rivals to move faster.
Smartwatch bolusing, advanced occlusion detection, and CGM integration set the stage for Sequel Med Tech’s game-changing debut.
Abbott’s flagship CGM now powers Tandem’s Control-IQ+ system—with more pump integrations and a ketone sensor on the horizon.
Tandem, Beta Bionics, Sequel Med Tech, and Ypsomed are the first to announce integration plans for Abbott’s dual-analyte sensor with more expected.
After hearing your stories, we brought in experts—and spoke to Dexcom—to unpack what’s going on with Dexcom G7 sensor failures.
The diabetes division will separate from its parent company. Could this unlock faster innovation—or is it more of the same with a new name?
The company will now open the waitlist for its newly FDA cleared CGM to current users after user feedback.
Sequel Med Tech announces support for the Eversense CGM as it prepares for the twiist insulin pump launch. Here's what you need to know.
Abbott's new app brings much needed upgrades like silence Low Alarms and control of all sensors under one umbrella.
The major insulin pump manufacturer sent out a survey asking its users which color they prefer for its upcoming tubeless pump.
The new sensor lasts 50% longer, but according to a Dexcom study, 1 out of 4 sensors won't last the entire lifespan.
A Community United documents the T1D community’s fight to get supplies into the hands of those affected by the fires.
